[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336552-105":59,"doc-detail-336552-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","development-of-a-disulfidptosis-related-lncrna-prognostic-signature-for-enhanced-prognostic-assessment-and-therapeutic-strategies-in-lung-squamous-cell-carcinoma","Development of a Disulfidptosis-Related lncRNA Prognostic Signature - for Enhanced Prognostic Assessment and Therapeutic Strategies in Lung Squamous Cell Carcinoma","","Limited treatment options and poor prognosis challenge lung squamous cell carcinoma (LUSC) care. Disulfidptosis is investigated for its role in cancer progression and patient outcomes. Using TCGA-LUSC gene expression matrices and clinical data, co-expression analysis identifies 209 disulfidptosis-related lncRNAs, while LASSO-Cox regression selects nine to build a prognostic model. Kaplan–Meier and ROC validate performance, and Cox analysis links risk score with overall survival. Immune relationships, therapy responsiveness, drug sensitivity, and C10orf55 functional evidence further support clinical utility.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/development-of-a-disulfidptosis-related-lncrna-prognostic-signature-for-enhanced-prognostic-assessment-and-therapeutic-strategies-in-lung-squamous-cell-carcinoma/336552/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/development-of-a-disulfidptosis-related-lncrna-prognostic-signature-for-enhanced-prognostic-assessment-and-therapeutic-strategies-in-lung-squamous-cell-carcinoma/336552.png","ImageObject",300,407,{"name":92,"@type":93},"Liam","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-07","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the study address in lung squamous cell carcinoma (LUSC)?","Question",{"text":112,"@type":113},"The study targets limited treatment options and poor prognosis in LUSC, where identifying biomarkers to predict outcomes and therapy response remains difficult.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the disulfidptosis-related lncRNA prognostic signature constructed?",{"text":117,"@type":113},"TCGA-LUSC expression and clinical data were used; co-expression analysis identified 209 related lncRNAs, and LASSO-Cox regression selected nine key lncRNAs to form the prognostic model.",{"name":119,"@type":110,"acceptedAnswer":120},"How was the prognostic model validated and interpreted?",{"text":121,"@type":113},"Model validity was confirmed using Kaplan–Meier and ROC curves, while Cox regression showed the risk score as an independent factor inversely correlated with overall survival; a nomogram further demonstrated predictive performance.",{"name":123,"@type":110,"acceptedAnswer":124},"What links did the study explore between the signature and treatment or biology?",{"text":125,"@type":113},"The work assessed immune function using ESTIMATE, CIBERSORT, and ssGSEA, evaluated immune therapy responsiveness with TIDE, screened drug sensitivity via GDSC, and performed functional evidence by silencing C10orf55 in SW900 cells to reduce invasiveness and migration potential.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},336552,1790023667,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":19,"preview_urls":150},8796095461564,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nDevelopment  \nof a disulfidptosis‑related lncRNA prognostic signature for enhanced  \nprognostic assessment and therapeutic strategies in lungsquamous cell carcinoma  \nAnkang Zhu, Yan Zong & Xingcai Gao *  \nLimited treatment options and poor prognosis present significant challenges in the treatment of lung squamous cell carcinoma (LUSC). Disulfidptosis impacts cancer progression and prognosis. We developed a prognostic signature using disulfidptosis‑related long non‑coding RNAs (lncRNAs) to predict the prognosis of LUSC patients. Gene expression matrices and clinical information for LUSC were downloaded from theTCGA database. Co‑expression analysis identified 209 disulfidptosis‑ related lncRNAs. LASSO‑Cox regression analysis identified nine key lncRNAs, forming the basis for establishing a prognostic model. The model’s validity was confirmed by Kaplan–Meier and ROC curves. Cox regression analysis identified the risk score (RS) as an independent prognostic factor inversely correlated with overall survival. A nomogram based on the RS demonstrated good predictive performance for LUSC patient prognosis. The relationship between RS and immune function was explored using ESTIMATE, CIBERSORT, and ssGSEA algorithms. According to the TIDE database, a negative correlation was found between RS and immune therapy responsiveness. The GDSC database revealed that 49 drugs were beneficial for the low‑risk group and 25 drugs for the high‑risk group. Silencing C10orf55 expression in SW900 cells reduced invasiveness and migration potential. In summary, this lncRNA model based on TCGA‑LUSC data effectively predicts prognosis and assists clinical decision‑making.  \nKeywords LncRNA, Lung squamous cell carcinoma, Disulfidptosis, Prognostic signature, Immunotherapy  \nAbbreviations  \nLUSC Lung squamous cell carcinoma LUAD Lung adenocarcinoma  \nPCD Programmed cell death  \nDRGs Disulfide bond pathology-related genes  \nlncRNA Long non-coding RNA TCGA The cancer genome atlas GO Gene ontology  \nBP Biological process  \nCC Cellular component  \nMF Molecular function  \nKEGG Kyoto encyclopedia of genes and genomes GSEA Gene set enrichment analysis  \nTMB Tumor mutation burden  \nssGSEA Single-sample gene set enrichment analysis  \nThe Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, China . * email: [gxc575788@sina.com](gxc575788@sina.com)  \n[www. nature.com/scientificreports/](www. nature.com/scientificreports/)  \nHRG  \nLRG  \nK-M  \nRS  \nDEGs  \nAUC  \nROC  \nCDK1  \nFDR  \nIC50  \nTIME  \nGDSC  \nTIDE  \nFBSqRT-PCR NSCLC  \nHigh-risk group Low-risk group Kaplan–Meier Risk Score  \nDifferentially expressed genes Area under the curve  \nReceiver operating characteristic Cyclin-dependent kinase 1  \nFalse discovery rate  \nHalf-maximal inhibitory concentration Tumor immune microenvironment Genomics of drug sensitivity in cancer Tumor Immune dysfunction and exclusion Fetal bovine serum  \nQuantitative real-time polymerase chain reaction Non-small cell lung cancer  \nLung cancer is one of the most formidable malignancies, with both incidence and mortality rates ranking first globally1. Lung squamous cell carcinoma (LUSC) and lung adenocarcinoma (LUAD) are the two major subtypes of lung cancer2. Compared to LUAD, LUSC has a poorer clinical prognosis and lacks targeted therapies. In recent years, with the development of radiotherapeutic agents and immunotherapy, the prognosis of LUSC patients has improved. However, their 5 year survival rate is still lower than 18%, and most patients eventually develop drug resistance3,4. Consequently, it is essential to identify appropriate biomarkers to forecast the outcome and treatment response in LUSC.  \nTargeting programmed cell death (PCD) for cancer treatment has long been a significant research focus. Genes related to PCD have played a crucial role in developing innovative cancer therapies. For example, since its introduction in 20","cbCaigQls7F8Epec","https://ap.wps.com/l/cbCaigQls7F8Epec","pdf",5163595,17,"English","# Background\n## Clinical need in LUSC\n## PCD and disulfidptosis\n## Role of lncRNAs\n# Methods\n## Data sources (TCGA)\n## Identification of disulfidptosis-related lncRNAs\n## Model building with LASSO-Cox\n# Results\n## Validation with Kaplan–Meier and ROC\n## Independent prognostic value of risk score\n## Nomogram for prediction\n## Immune microenvironment and therapy responsiveness\n## Drug sensitivity analysis\n## In vitro functional validation","[{\"question\":\"What problem does the study address in lung squamous cell carcinoma (LUSC)?\",\"answer\":\"The study targets limited treatment options and poor prognosis in LUSC, where identifying biomarkers to predict outcomes and therapy response remains difficult.\"},{\"question\":\"How was the disulfidptosis-related lncRNA prognostic signature constructed?\",\"answer\":\"TCGA-LUSC expression and clinical data were used; co-expression analysis identified 209 related lncRNAs, and LASSO-Cox regression selected nine key lncRNAs to form the prognostic model.\"},{\"question\":\"How was the prognostic model validated and interpreted?\",\"answer\":\"Model validity was confirmed using Kaplan–Meier and ROC curves, while Cox regression showed the risk score as an independent factor inversely correlated with overall survival; a nomogram further demonstrated predictive performance.\"},{\"question\":\"What links did the study explore between the signature and treatment or biology?\",\"answer\":\"The work assessed immune function using ESTIMATE, CIBERSORT, and ssGSEA, evaluated immune therapy responsiveness with TIDE, screened drug sensitivity via GDSC, and performed functional evidence by silencing C10orf55 in SW900 cells to reduce invasiveness and migration potential.\"}]","Development of a Disulfidptosis-Related lncRNA Prognostic Signature - for Enhanced Prognostic Assessment and Therapeutic Strategies in Lung Squamous Cell Carcinoma | PDF",1790015587,43,[151,155,159,163],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0dd8ec0f21ab31854e768eff6143afd9.webp",983,1291,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/65a0437148d8b39421c0bb76eaf6410a.webp",982,1290,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/70b8eb1cd2070af6fe1d392a89c86a85.webp",981,1289,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a85e049c1220a031526a0f3ae3e52e3e.webp",980,1287]